Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nab-paclitaxel and Pyrotinib in Adjuvant Therapy for Early HER2-positive Breast Cancer
NCT04659499Phase 2Completed
- Sponsor
- Peking Union Medical College Hospital
- Start
- Jan 2021
- Primary completion
- Feb 2026
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of pyrotinib in breast cancer, sponsored by Peking Union Medical College Hospital. Started Jan 2021; status: completed.
02
Drugs
pyrotinib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT04659499.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04659499.